title: Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?
authors: Sorbonne Université-Université Paris 06 (UPMC), ACTION Study Group, INSERM UMR_S 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.
authors: Johanne
authors: J
authors: Silvain
authors: Sorbonne Université-Université Paris 06 (UPMC), ACTION Study Group, INSERM UMR_S 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France.
authors: Mathieu
authors: M
authors: Kerneis
authors: Sorbonne Université-Université Paris 06 (UPMC), ACTION Study Group, INSERM UMR_S 1166, ICAN, Institut de Cardiologie, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: gilles.montalescot@aphp.fr.
authors: Gilles
authors: G
authors: Montalescot
mesh_terms: D054058:Acute Coronary Syndrome / Q000628:therapy*; D000241:Adenosine / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011300:Preoperative Care / Q000379:methods*; D013988:Ticlopidine / Q000031:analogs & derivatives*; D014336:Troponin / Q000097:blood*
chemical_list: D014336:Troponin; D000241:Adenosine; D013988:Ticlopidine
keywords: acute coronary syndrome; coronary artery disease; percutaneous coronary intervention; platelet aggregation inhibitors; prasugrel hydrochloride